Izraelis - anglų - Ministry of Health

medison pharma ltd - cysteamine as bitartrate - hard capsule - cysteamine as bitartrate 150 mg - mercaptamine - cystagon is indicated for the treatment of proven nephropathic cystinosis.cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.

Izraelis - anglų - Ministry of Health

medison pharma ltd - cysteamine as bitartrate - hard capsule - cysteamine as bitartrate 150 mg - mercaptamine - cystagon is indicated for the treatment of proven nephropathic cystinosis.cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.

Izraelis - anglų - Ministry of Health

medison pharma ltd - cysteamine as bitartrate - hard capsule - cysteamine as bitartrate 150 mg - mercaptamine - cystagon is indicated for the treatment of proven nephropathic cystinosis.cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.

Izraelis - anglų - Ministry of Health

medison pharma ltd - cysteamine as bitartrate - hard capsule - cysteamine as bitartrate 50 mg - mercaptamine - cystagon is indicated for the treatment of proven nephropathic cystinosis.cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.

Izraelis - anglų - Ministry of Health

medison pharma ltd - cysteamine as bitartrate - hard capsule - cysteamine as bitartrate 50 mg - mercaptamine - cystagon is indicated for the treatment of proven nephropathic cystinosis.cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.

Izraelis - anglų - Ministry of Health

medison pharma ltd - betaine anhydrous - powder for solution - betaine anhydrous 1 g/g - betaine - treatment of homocystinuria.

Izraelis - anglų - Ministry of Health

medison pharma ltd - mercaptamine as hydrochloride - ophthalmic solution - mercaptamine as hydrochloride 3.8 mg - mercaptamine - cystadrops is indicated for the treatment of corneal cystine crystal deposits in adults and children from 2 years of age with cystinosis.

Izraelis - anglų - Ministry of Health

medison pharma ltd - mercaptamine as hydrochloride - ophthalmic solution - mercaptamine as hydrochloride 3.8 mg - mercaptamine - cystadrops is indicated for the treatment of corneal cystine crystal deposits in adults and children from 2 years of age with cystinosis.

Izraelis - anglų - Ministry of Health

medison pharma ltd - zanubrutinib - capsules - zanubrutinib 80 mg - • brukinsa is indicated for the treatment of adult patients with mantle cell lymphoma (mcl) who have received at least one prior therapy.• brukinsa is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm).• brukinsa is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (mzl) who have received at least one anti-cd20-based regimen.• brukinsa is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll).

Izraelis - anglų - Ministry of Health

medison pharma ltd - lisdexamfetamine dimesylate - capsules - lisdexamfetamine dimesylate 50 mg - lisdexamfetamine - vyvanse is a central nervous system (cns) stimulant indicated for the treatment of attention deficit hyperactivity disorder (adhd) in patients ages 6 years and above.vyvanse is indicated for the treatment of moderate to severe binge eating disorder (bed) for patient over 18 years.limitation of use:vyvanse is not indicated or recommended for weight loss. use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. the safety and effectiveness of vyvanse for the treatment of obesity have not been established